IMPEDIMED LIMITED — Capital/Financing Update 2021

Nov 2, 2021

==> picture [230 x 54] intentionally omitted <==

3 November 2021

ASX ANNOUNCEMENT

IMPEDIMED’S SHARE PURCHASE PLAN OPENS

The Share Purchase Plan ( SPP ) announced by ImpediMed Limited ( ImpediMed or the Company ) (ASX: IPD) on Wednesday, 27 October 2021 opens today. Eligible Shareholders in Australia and New Zealand now have the opportunity to apply for up to A$30,000 of new fully paid ordinary shares in ImpediMed ( SPP Shares ) without incurring brokerage, commissions, or other transaction costs.

The SPP follows ImpediMed’s successfully completed A$35 million institutional placement at an issue price of A$0.1525 per share ( Placement ).

Details of the SPP

Shareholders are eligible to participate in the SPP if, as at 7:00pm (AEDT) on Tuesday, 26 October 2021, they had a registered address in Australia or New Zealand ( Eligible Shareholders ).

The SPP is also being extended to Eligible Shareholders who are custodians to participate in the SPP on behalf of certain eligible beneficiaries on the terms and conditions set out in the SPP Booklet.

The SPP aims to raise A$5 million and is not underwritten. Depending on the level of demand, ImpediMed may decide to accept applications (in whole or part) that result in the SPP raising more or less than this amount, in its absolute discretion.

The issue price of the SPP Shares will A$0.1525 per share, being the same issue price as the Placement.

Once issued, the SPP Shares will rank equally with existing ImpediMed’ shares.

The SPP is expected to close at 5:00pm (AEDT) on Thursday, 11 November 2021 ( Closing Date ).

The SPP is subject to the terms and conditions set out in the attached Share Purchase Plan Booklet ( SPP Booklet ). The SPP Booklet is being sent to Eligible Shareholders today. Eligible Shareholders are encouraged to read the SPP Booklet carefully and, if they are in any doubt about whether to participate in the SPP offer, to consult their stockbroker, accountant, financial adviser, solicitor or other professional adviser.

To apply for SPP Shares, Eligible Shareholders must by 5.00pm (AEDT) on the Closing Date, either:

• apply through the SPP website at www.impedimed.com/about/investors/ and make a payment directly via BPAY® (Australian Shareholders only); or

• apply through the SPP website at www.impedimed.com/about/investors/ and make a payment directly via EFT (New Zealand Shareholders only).

1

ImpediMed Limited ASX Announcement

==> picture [159 x 38] intentionally omitted <==

Further Information

If you are an Eligible Shareholder and would like further information, please call ImpediMed’s Investor Relations, between 8.30am and 5.00pm (AEDT) Monday to Friday on +61 407 431 432 before the SPP offer closes.

In addition, further details about the Placement and SPP are set out in the Investor Presentation released to the ASX on Wednesday, 27 October 2021. The Investor Presentation contains important information including key risks of an investment in ImpediMed.

Authorised for release by the Board of Directors of ImpediMed Limited

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, protein calorie malnutrition and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

2

ImpediMed Limited ASX Announcement